Breast Cancer Care
 

Presented by

Charles Cox, MD
Professor and Director of Breast Surgery
University of South Florida Health

Linda Han, MD
Director of Breast Oncology
Parkview Cancer Institute

and
Cardinal Health Nuclear & Precision Health Solutions

 



 

Choose from 2 presentations


Thursday, March 21st, 3-4pm ET

Tuesday, April 2nd, 12-1pm ET
 

Register Now

Melanoma Care
 

Presented by

Adam Berger, MD
Professor of Surgery
Chief, Surgical Oncology
Department of Surgery
Thomas Jefferson University Hospital

Charles Intenzo, MD
Professor of Radiology
Director, Nuclear Medicine & Molecular Imaging
Department of Radiology
Thomas Jefferson University Hospital 

and
Cardinal Health Nuclear & Precision Health Solutions

 


Presentation information

Wednesday, February 20th, 12-1pm ET


 

Register Now

Squamous Cell Carcinoma of the Oral Cavity Care

Presented by

Stephen Y. Lai, MD, PhD, FACS
Professor
Head and Neck Surgery
Molecular and Cellular Oncology
Radiation Oncology
The University of Texas MD Anderson Cancer Center

and
Cardinal Health Nuclear & Precision Health Solutions

 

 

 



Presentation information

Wednesday, February 27th, 3-4pm ET


 

Register Now

 

 


LYMPHOSEEK® Indication and Important Safety Information
LYMPHOSEEK® is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.

Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information
In clinical trials with LYMPHOSEEK®, no serious hypersensitivity reactions were reported, however LYMPHOSEEK® may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of LYMPHOSEEK®, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK® administration, and patients observed for signs or symptoms of hypersensitivity following injection. Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%)

Full LYMPHOSEEK® prescribing information can be found at: lymphoseek.com